A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

INTRODUCTION: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). However, the efficacy of standard subsequent therapi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ther Adv Med Oncol
Hoofdauteurs: Li, Yi, Li, Wei, Gong, Chengcheng, Zheng, Yabin, Ouyang, Quchang, Xie, Ning, Qu, Qing, Ge, Rui, Wang, Biyun
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2021
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202336/
https://ncbi.nlm.nih.gov/pubmed/34178122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211022890
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items